Clinical Trials Sponsored by Oxford BioTherapeutics Ltd

Total 109 results

Oxford BioTherapeutics Ltd

Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Solid Tumor

United States, Belgium, Spain, France, Greece
NovaRock Biotherapeutics, Ltd

Recruiting

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

Advanced Malignant Tumors

China
TILT Biotherapeutics Ltd.

Recruiting

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy (TUNIMO)

Solid Tumor

Finland
TILT Biotherapeutics Ltd.

Active, not recruiting

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL)

Metastatic Melanoma

France, Denmark
NovaRock Biotherapeutics, Ltd

Recruiting

A Study of NBL-028 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
NovaRock Biotherapeutics, Ltd

Not yet recruiting

Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
TILT Biotherapeutics Ltd.

Recruiting

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (AVENTIL)

Melanoma | Head and Neck Squamous Cell Carcinoma

United States, Finland
NovaRock Biotherapeutics, Ltd

Completed

A Study of NBL-012 in Healthy Chinese Subjects

Healthy Subjects

China
Innostellar Biotherapeutics Co.,Ltd

Recruiting

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Neovascular Age-Related Macular Degeneration

China
Innostellar Biotherapeutics Co.,Ltd

Active, not recruiting

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Inherited Retinal Dystrophy Associated With RPE65 Mutations

China
Innostellar Biotherapeutics Co.,Ltd

Recruiting

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Inherited Retinal Dystrophy

China
Innostellar Biotherapeutics Co.,Ltd

Recruiting

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-Related Macular Degeneration

China
Oxford Pharmascience Ltd

Completed

Pilot Study of OXP005 to Assess Gastroduodenal Irritation

Gastroduodenal Erosions

United Kingdom
Oxford Pharmascience Ltd

Completed

Phase I Study PK Study With OXP005 and Naprosyn

Pharmacokinetics

United Kingdom
Oxford Pharmascience Ltd

Completed

Impact of Excipients on Pharmacokinetics of OXPzero(TM) Ibuprofen

Pharmacokinetics

United Kingdom
Oxford Pharmascience Ltd

Completed

Pilot Study of OXP001 and Brufen in Healthy Subjects

NSAID Related Gastric Irritation

United Kingdom
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related Disease

China
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

China
Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

Advanced Solid Tumor

Australia, China
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Multiple Myeloma

China
Nanjing IASO Biotherapeutics Co.,Ltd

Recruiting

A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (FUMANBA-1)

Multiple Myeloma

China
Shanghai EpimAb Biotherapeutics Co., Ltd.

Terminated

A Study of EMB-02 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

China, Australia, United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Unknown

CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors

Solid Tumor | CAR

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

B-cell Non-Hodgkin's Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

CAR-T for r/r Malignant Tumors in Children

Child, Only | Malignant Tumor | CAR-T

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Not yet recruiting

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid Arthritis | Systemic Lupus Erythematosus | Systemic Sclerosis | Immune Thrombocytopenia | Sjogren's Syndrome | Idiopathic Inflammatory Myopathies | Primary Biliary Cholangitis
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
EpimAb Biotherapeutics (Suzhou)Co., Ltd.

Recruiting

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Advanced/Metastatic Solid Tumors | Relapse/Refractory Lymphoma

China, Australia
Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Relapsed or Refractory Multiple Myeloma

China, Australia
Oxford Vacmedix UK Ltd.

Recruiting

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer

United Kingdom
Shanghai EpimAb Biotherapeutics Co., Ltd.
Covance

Recruiting

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Neoplasms | Neoplasm Metastasis | Non-Small-Cell Lung Cancer

United States, China
University of Oxford
Optellum Ltd.

Completed

IDEAL: Artificial Intelligence and Big Data for Early Lung Cancer Diagnosis Study (IDEAL)

Lung Cancer | Pulmonary Nodule, Solitary | Pulmonary Nodule, Multiple

United Kingdom
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Oxford Pharmascience Ltd
Quotient Clinical

Completed

Pilot Study of OXP001(2) and Brufen in Healthy Subjects

Gastroduodenal Erosions

United Kingdom
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | CAR

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | CAR

China
Conjupro Biotherapeutics, Inc.
CSPC-NBP Pharmaceutical Co., Ltd.

Withdrawn

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Breast Cancer | Peripheral Neuropathy
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Follicular Lymphoma | B Cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Plasma Cell Neoplasm | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Primary Cutaneous Follicle Centre Lymphoma

China
University of Oxford
Big Health Ltd.

Recruiting

A Study of Digital Cognitive Behavioural Therapy for Insomnia in Fibromyalgia (Pain-LESS)

Fibromyalgia

United Kingdom
University of Oxford
Clasado Biosciences Ltd

Completed

The Effects of Prebiotics on Cognitive Functioning and Weight Gain in Psychosis (Prepsy)

Schizophrenia

United Kingdom
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Not yet recruiting

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

CD19-positive Relapsed or Refractory B-cell Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
University of Oxford
Clasado Biosciences Ltd

Unknown

Oxford Study of Prebiotics in Children (OxPiC)

Behaviour

United Kingdom
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

CAR | Malignant Tumors

China
Conjupro Biotherapeutics, Inc.
CSPC Megalith Biopharmaceutical Co., Ltd.

Withdrawn

Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

Gastric Cancer | Pancreatic Cancer
Conjupro Biotherapeutics, Inc.
CSPC Ouyi Pharmaceutical Co., Ltd.

Completed

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

Hypertension

United States

Clinical Trials Sponsored by Oxford BioTherapeutics Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations